98215-44-2

Upstream product

• 100523-84-0 2-bromothiophene-4-carboxylic acid 

Downstream Products

• 98215-51-1 5-Bromo-thiophene-3-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide 
• 1461640-05-0 5-bromo-N-(3-methoxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-22-0 N-(3-methoxybenzyl)-5-(3-methoxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-20-8 N,5-bis(3-methoxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-26-4 N-(3-hydroxybenzyl)-5-(3-hydroxyphenyl)-N-methylthiophene-3-carboxamide 
• 1620518-24-2 N,5-bis(3-hydroxyphenyl)-N-methylthiophene-3-carboxamide 

Relevant academic research and scientific papers

Synthesis and antitumour activity of new derivatives of flavone-8- acetic acid (FAA). Part 31): 2-Heteroaryl derivatives

A range of 14 derivatives of flavone-8-acetic acid (FAA) with a heterocyclic substituent in place of the 2-phenyl group have been prepared and their anti-tumour activity evaluated in vitro against a panel of human and murine tumour cell lines and in vivo against MAC 15A. Some of the compounds, notably 2c,d and s, showed significant in vivo activity and these require further studies in order to evaluate their potential for development.

TRICYCLIC CARBOXAMIDES FOR CONTROLLING ARTHROPODS

The invention relates, inter alia, to compounds of general formula (I). The invention also relates to methods for synthesizing the compounds of formula (I). The compounds according to the invention are in particular suitable for controlling insects, arachnids and nematodes in agricultural applications and for controlling ectoparasites in veterinary medicine.

Substituted thiophene compound Preparation method and application thereof (by machine translation)

The invention relates to a thiophene compound represented by general formula I, a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the thiophene compound and application thereof. The thiophene compound and a pharmaceutically acceptable salt thereof are taken as a novel estrogen-related receptor α (ERR RR) inverse agonist. These compounds can be used to treat diseases associated with ERR and ERR RR, such as cancer, osteoporosis, diabetes, anti-aging, slimming, and the like. After further optimization and screening, the drug is expected to be developed into novel drugs for preventing and treating tumors or other ERR RR related diseases. (by machine translation)

A Planar-Chiral Rhodium(III) Catalyst with a Sterically Demanding Cyclopentadienyl Ligand and Its Application in the Enantioselective Synthesis of Dihydroisoquinolones

The rapid development of enantioselective C?H activation reactions has created a demand for new types of catalysts. Herein, we report the synthesis of a novel planar-chiral rhodium catalyst [(C5H2tBu2CH2tBu)RhI2]2 in two steps from commercially available [(cod)RhCl]2 and tert-butylacetylene. Pure enantiomers of the catalyst were obtained through separation of its diastereomeric adducts with natural (S)-proline. The catalyst promoted enantioselective reactions of aryl hydroxamic acids with strained alkenes to give dihydroisoquinolones in high yields (up to 97 %) and with good stereoselectivity (up to 95 % ee).

Synthesis, Nicotinic Acetylcholine Receptor Binding, and in Vitro and in Vivo Pharmacological Properties of 2′-Fluoro-(substituted thiophenyl)deschloroepibatidine Analogues

The synthesis, nAChR in vitro and in vivo pharmacological properties of 2′-fluoro-3′-(substituted thiophenyl)deschloroepibatidine analogues (5a-f, 6a-d, and 7a-c) are presented herein. All had subnanomolar affinity at α4β2*-nAChRs. Contrary to lead structure epibatidine, a potent nAChR agonist, all were potent α4β2- and α3β4-AChR antagonists in an in vitro functional assay. In vivo, the compounds were also nAChR antagonists with various degrees of agonist activity. Compounds 5e, 5f, 6a, 6c, 6d, and 7c had no agonist effects in the tail-flick, hot-plate, hypothermia, or spontaneous activity tests, whereas 5a-d, 7a and 7b did not have agonist activity in the tail-flick and hot-plate tests but, like varenicline, were agonists in the hypothermia and spontaneous activity tests. Compound 6b had agonist activity in all four in vivo tests. All the compounds were antagonists of nicotine-induced antinociception in the tail-flick test, and all except 5c, 5d, 5f, and 6b were antagonists of nicotine-induced antinociception in the hot-plate test. Compound 7c, which had a Ki = 0.86 nM in the binding assay similar potency at α4β2/α3β4 with selectivity relative to α7 nAChRs, had an AD50 value of 0.001 μg/kg in the tail-flick test with no agonist activity in the in vitro or in vivo test had one of the more interesting profiles.

Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities

17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) is responsible for the oxidation of the highly active estradiol (E2) and testosterone (T) into the less potent estrone (E1) and Δ4-androstene-3,17-dione (Δ4-AD), respectively. As 17β-HSD2 is present in bones and as estradiol and testosterone are able to induce bone formation and repress bone resorption, inhibition of this enzyme could be a new promising approach for the treatment of osteoporosis. Herein, we describe the design, the synthesis and the biological evaluation of 24 new 17β-HSD2 inhibitors in the 5-substituted thiophene-2-carboxamide class. Structure-activity and structure-selectivity relationships have been explored by variation of the sulfur atom position in the central core, exchange of the thiophene by a thiazole, substitution of the amide group with a larger moiety, exchange of the N-methylamide group with bioisosteres like N-methylsulfonamide, N-methylthioamide and ketone, and substitutions at positions 2 and 3 of the thiophene core with alkyl and phenyl groups leading to 2,3,5-trisubstituted thiophene derivatives. The compounds were evaluated on human and mouse enzymes. From this study, a novel highly potent and selective compound in both human and mouse 17β-HSD2 enzymes was identified, compound 21 (IC 50(h17β-HSD2) = 235 nM, selectivity factor toward h17β-HSD1 = 95, IC50 (m17β-HSD2) = 54 nM). This new compound 21 could be used for an in vivo proof of principle to demonstrate the true therapeutic efficacy of 17β-HSD2 inhibitors in osteoporosis. New structural insights into the active sites of the human and mouse enzymes were gained.

Selective photoinduced energy transfer from a thiophene rotaxane to acceptor

An energy transfer process was investigated using cyclodextrin- oligothiophene rotaxanes (2T-[2]rotaxane). The excited energy of 2T-[2]rotaxane is transferred to the sexithiophene derivative which is included in the cavity of β-CD stoppers of 2T-[2]rotaxane.

THIENOPYRIDAZINES AS IKK INHIBITORS

The invention is concerned with a compound of formula (I): or a pharmaceutically acceptable salt, a solvate or a prodrug thereof, wherein A, Y, Z and Rl are as defined in the description and the claims. These compounds inhibit IKK and can be used as medicaments.

Poly(alkyl thiophene-3-carboxylates). Synthesis, properties and electroluminescence studies of polythiophenes containing a carbonyl group directly attached to the ring

Improved synthetic methodology for poly(3-hexyl- and 3- octyloxycarbonylthiophene-2,5-diyl) (1a and 1b) is reported. M(n) = 6700 and 9400 (M(w)/M(n) = 2.5 and 3.2), λ(max) for fluorescence emission = 600 and 610 nm and λ(max) for electroluminescence = 600 and 615 nm, for 1a and 1b respectively. The 1H NMR spectra required that pentads be considered to explain the spectra. That is the four nearest neighbours to a given ring influence the 1H NMR spectrum. Electroluminescence efficiencies of 0.016% and 0.018% were observed for devices made from 1a and 1b, respectively. A bilayer device of ITO/poly(3-octylthiophene)/1b/A1 emitted at 646 nm, the same wavelength where poly(3-octylthiophene) itself emits. The efficiency was low but was an order of magnitude greater than for poly(3-octylthiophene) itself. Regioregular (HH-TT) poly(4,4'-bis(hexyl- and octyloxycarbonyl)[2,2'- bithiophene]-5,5'-diyl) (3a and 3b) were also prepared via the Ullmann reaction and M(n) = 7900 and 11000 respectively. Films of 3a and 3b were yellow in color and showed λ(max) = 377 and 381 nm respectively, about 55-80 nm blue shifted compared with 1a and 1b. This is due to the large rotational barrier in the HH dyads which reduces the effective conjugation length in 3a and 3b. 3a and 3b showed bright fluorescence and electroluminescence with emission of yellow light. Electroluminescence efficiencies were 8.5 x 10-3% and 4.7 x 10-3%, respectively.